In the DESTINY-PanTumor02 trials, trastuzumab-deruxtecan (T-DXd) demonstrated exceptional efficacy, particularly in patients with advanced or metastatic HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.